Pacific Biosciences of California, Inc. (PACB)
Stock Price Chart
Key Info
| Market Cap | 887.85M |
| Revenue (ttm) | 82.52M |
| Net Income (ttm) | -51.04M |
| Shares Out | 154.41M |
| EPS (ttm) | -0.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 14, 2020 |
| Last Price | $5.75 |
| Previous Close | $5.61 |
| Change ($) | 0.14 |
| Change (%) | 2.50% |
| Day's Open | 5.50 |
| Day's Range | 5.46 - 5.79 |
| Day's Volume | 1,744,090 |
| 52-Week Range | 2.20 - 5.94 |
More Stats
| Market Cap | 887.85M |
| Enterprise Value | 811.85M |
| Earnings Date (est) | Oct 29, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 154.41M |
| Float | 151.00M |
| EPS (basic) | -0.33 |
| EPS (diluted) | -0.33 |
| FCF / Share | 0.10 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | 1.66% |
| Payout Ratio | n/a |
| Shares Short | 17.85M |
| Short Ratio | 18.18 |
| Short % of Float | 12.05% |
| Beta | 1.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | 60.28 |
| PS Ratio | 10.76 |
| PB Ratio | 20.59 |
| Revenue | 82.52M |
| Operating Income | -102.26M |
| Net Income | -51.04M |
| Free Cash Flow | 14.73M |
| Net Cash | 76.00M |
| Net Cash / Share | 0.49 |
| Gross Margin | 41.90% |
| Operating Margin | -123.93% |
| Profit Margin | -61.80% |
| FCF Margin | 17.85% |
| ROA | -28.68% |
| ROE | -87.14% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.89 | 78.63 | 93.47 | 90.71 | 92.78 | 60.59 | 28.18 | 25.98 | 33.86 | 1.67 |
| Revenue Growth | 15.6% | -15.88% | 3.04% | -2.23% | 53.12% | 115.02% | 8.46% | -23.27% | 1922.88% | - |
| Gross Profit | 34.58 | 25.10 | 34.66 | 44.16 | 53.45 | 23.40 | 6.42 | 0.94 | 13.03 | 1.67 |
| Operating Income | -101 | -101 | -89.78 | -71.24 | -29.13 | -62.85 | -77.54 | -94.34 | -110 | -140 |
| Net Income | -84.13 | -103 | -92.19 | -74.38 | -31.70 | -66.16 | -79.29 | -94.47 | -109 | -140 |
| Shares Outstanding | 153 | 135 | 106 | 89.15 | 75.61 | 70.48 | 62.78 | 55.73 | 53.87 | 9.94 |
| Earnings Per Share | -0.55 | -0.76 | -0.87 | -0.83 | -0.42 | -0.94 | -1.26 | -1.69 | -2.03 | -14.10 |
| Operating Cash Flow | -78.31 | -66.43 | -67.52 | -67.93 | -47.89 | -51.47 | -29.83 | -76.82 | -103 | -122 |
| Capital Expenditures | -2.84 | -1.85 | -10.39 | -8.20 | -2.97 | -1.61 | -0.91 | -1.70 | -9.28 | -5.26 |
| Free Cash Flow | -81.15 | -68.28 | -77.91 | -76.13 | -50.86 | -53.08 | -30.74 | -78.53 | -112 | -127 |
| Cash & Equivalents | 49.10 | 102 | 62.87 | 71.98 | 82.27 | 101 | 113 | 101 | 177 | 284 |
| Total Debt | 61.67 | 14.66 | 13.64 | 16.11 | 14.95 | 13.99 | 13.35 | 2.79 | 2.93 | 3.04 |
| Net Cash / Debt | -12.57 | 87.70 | 49.24 | 55.87 | 67.32 | 87.36 | 99.18 | 97.79 | 175 | 281 |
| Assets | 148 | 170 | 144 | 138 | 131 | 124 | 136 | 130 | 218 | 306 |
| Liabilities | 93.07 | 56.21 | 57.98 | 53.22 | 57.57 | 69.44 | 67.01 | 20.30 | 26.85 | 25.88 |
| Book Value | 54.92 | 114 | 86.10 | 84.67 | 73.54 | 54.95 | 69.18 | 109 | 191 | 280 |
Company Profile
Company Details
| Full Name | Pacific Biosciences of California, Inc. |
| Country | United States |
| Employees | 404 |
| CEO | Michael W. Hunkapiller |
Stock Information
| Ticker Symbol | PACB |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NASDAQ: PACB |
| IPO Date | October 27, 2010 |
Description
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and exonucleases. In addition, it provides binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprises reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences has collaboration with Asuragen to develop assays for carrier screening and other applications based on SMRT sequencing technology and AmplideX PCR chemistry. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.